Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough Asmanex Clears FDA; Manufacturing Will Begin This Fall

Executive Summary

Schering-Plough will not launch the newly approved asthma therapy Asmanex (mometasone furoate inhalation powder) before autumn

You may also be interested in...



Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD

Fixed-dose therapy will combine Novartis' investigational beta2-agonist indacaterol with Schering-Plough's Asmanex.

Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol

Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4

Schering Looking To Expand Therapeutic Frontiers Beyond Cholesterol

Schering-Plough is positioning itself to branch out from its cholesterol base into other therapeutic areas, CEO Fred Hassan said at the Morgan Stanley CEOs Unplugged investor conference on Jan. 4

Related Content

Topics

UsernamePublicRestriction

Register

PS045619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel